M-M-R II
Details for M-M-R II vaccine and its components.
Sponsor:
Merck Sharp & Dohme (Australia)
Administration route:
Intramuscular injection, Subcutaneous injection
Vaccine group:
Combination vaccines
Registered for use in people aged ≥12 months.
MMR — measles-mumps-rubella combination vaccine
Lyophilised pellet in a monodose vial with separate diluent.
Each 0.5 mL reconstituted dose contains:
- ≥1000 tissue culture infectious dose 50% (TCID50) of live attenuated measles virus (Enders’ attenuated Edmonston strain)
- ≥12,500 TCID50 of live attenuated mumps virus (Jeryl Lynn B level strain)
- ≥1000 TCID50 of live attenuated rubella virus (Wistar RA 27/3 strain)
- 14.5 mg sorbitol
- 1.9 mg sucrose
- 14.5 mg hydrolysed porcine gelatin
- ≤0.3 mg recombinant human albumin
- <1 ppm fetal bovine serum
- 25 µg neomycin
For detailed advice on vaccine dosage, administration, contraindications and precautions, please visit the relevant disease chapter.
Page history
Last updated:
23 April 2019
Last reviewed:
23 April 2019
Definitions
- MMR
- measles-mumps-rubella
Printed content may be out of date. For up to date information, always refer to the digital version: https://immunisationhandbook.health.gov.au/vaccines/m-m-r-ii.